Hepatocellular Carcinoma
Conditions
Keywords
Hepatocellular Carcinoma, TACE, TACE failure, TACE refractoriness, TAI, Sorafenib
Brief summary
Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not specify the criteria for repeating TACE. The study,conducted in Europe ，recently published in the journal of Hepatology shows the ART score of \>=2.5 prior the second TACE identifies patients with a dismal prognosis who may not profit from further TACE sessions. However,in clinical practice，we also found some patients who showed TACE-resistant at the beginning of treatment may access to get objective response of retreatment with transcatheter arterial infusion (TAI). So the investigators conduct this prospective,randomized controlled study to find out whether the patient who showed TACE-resistant can obtain survival benefit from retreatment with TAI.
Detailed description
Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, intermediate-stage HCC includes a heterogeneous population of patients with varying tumour burdens, liver function (Child-Pugh A or B) and disease aetiology.This suggests that not all patients with intermediate-stage HCC will derive similar benefit from transcatheter arterial infusion (TAI), and that some patients may benefit from other treatment options. Repetition of TACE is based on evidence suggesting that one cycle of TACE may not be sufficient for effective treatment of intermediate-stage HCC and repeating TACE prolongs survival. However, intermediate-stage HCC patients often have unsatisfactory clinical outcomes with repeated TACE and there is not sufficiently addressed by existing guidelines include the criteria for repeating TACE and recommendations about the number of TACE cycles to be repeated before switching to another or no treatment.The study,recently published in the journal of Hepatology shows the ART score of \>=2.5 prior the second TACE identifies patients with a dismal prognosis who may not profit from further TACE sessions.In clinical practice，however, we also found some patients who showed TACE-resistant at the beginning of treatment may access to get objective response of retreatment with TAI. So we conduct this prospective,randomized controlled study to find out whether the patient who showed TACE-resistant can obtain survival benefit from retreatment with TAI.
Interventions
PROCEDURETAI of FOLFOX
Retreatment with TAI: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
DRUGSorafenib
Accept sorafenib.
Sponsors
Kaiping Central Hospital
Guangzhou No.12 People's Hospital
Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Male or female patients， \> 18 years and \<=70 years old diagnosed with HCC according to the European Association for the Study of the Liver (EASL) diagnostic criteria * The patient has received 2 session of TACE * TACE failure/refractoriness by Liver Cancer Study Group of Japan (LCSGJ) criteria * Cirrhotic status of Child-Pugh class A * The following laboratory parameters: * Platelet count ≥ 60,000/µL * Hemoglobin ≥ 8.5 g/dL * Total bilirubin ≤ 1.5 mg/dL Serum albumin ≥ 35 g/L * ASL and AST ≤ 5 x upper limit of normal * Serum creatinine ≤ 1.5 x upper limit of normal * INR ≤ 1.5 or PT/APTT within normal limits * Absolute neutrophil count (ANC) \>1,500/mm3 * Ability to understand the protocol and to agree to and sign a written informed consent document
Exclusion criteria
* Patients with complete response (CR) after the first TACE did not receive a further TACE session * Eastern Cooperative Oncology Group (ECOG) \>1 * Known history of HIV * History of organ allograft * Known or suspected allergy to the investigational agents or any agent given in association with this trial. * Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy * Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry. * Serious non-healing wound, ulcer, or bone fracture * Evidence of bleeding diathesis. * Any other hemorrhage/bleeding event \> CTCAE Grade 3 within 4 weeks of first dose of study drug * Severe Arterioportal Shunts or Arteriavein Shunts * Known metastatic disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival | 1 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse Events | 30 days | All severe adverse events for the entire course of treatment |
| overall survival | 1 year | — |
Countries
China
Outcome results
None listed